Abstract

Next-generation sequencing of solid tumors has revealed variable signatures of immunogenicity across tumors, but underlying molecular characteristics driving such variation are not fully understood. Although expression of endogenous retrovirus (ERV)-containing transcripts can provide a source of tumor-specific neoantigen in some cancer models, associations between ERV levels and immunogenicity across different types of metastatic cancer are not well established. We performed bioinformatics analysis of genomic, transcriptomic, and clinical data across an integrated cohort of 199 patients with metastatic breast, colorectal, and pancreatic ductal adenocarcinoma tumors. Within each cancer type, we identified a subgroup of viral mimicry tumors in which increased ERV levels were coupled with transcriptional signatures of autonomous antiviral response and immunogenicity. In addition, viral mimicry colorectal and pancreatic tumors showed increased expression of DNA demethylation gene TET2 Taken together, these data demonstrate the existence of an ERV-associated viral mimicry phenotype across three distinct metastatic cancer types, while indicating links between ERV abundance, epigenetic dysregulation, and immunogenicity.

Highlights

  • Negative modulation of the immunogenic potential of tumor cells is recognized as a key step in cancer development and progression [1]

  • For colorectal and pancreatic ductal adenocarcinoma (PDAC) tumors showing elevated endogenous retrovirus (ERV) levels concomitant with signatures of antiviral response, we observed significant increases in TET2 mRNA

  • To investigate ERV levels across distinct metastatic tumor types, we leveraged whole-transcriptome RNA sequencing (RNA-seq) data generated by the Personalized Oncogenomics (POG) program [17]

Read more

Summary

Introduction

Negative modulation of the immunogenic potential of tumor cells is recognized as a key step in cancer development and progression [1]. Immunotherapeutic regimes such as immune checkpoint blockade aim to harness the endogenous antitumor response machinery to eliminate tumor cells with high specificity [2]. Tumor mutation burden (TMB) has been shown to be a strong predictor of immunotherapy response in cancer types with high mutation rates such as melanoma [4, 5] and non–small cell. Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call